Multiple myeloma is a type of cancer involving the plasma cells of the blood with its recent preclinical investigation has found the disease to be highly sensitive towards an advanced experimental therapy.
Plasma cells are a part of the bone marrow and these cells are extremely important for immune function of the body. Our immune system consists of different types of cells working cohesively to function as a unit to diffuse each and every infections and several diseases. Lymphocytes, a most important part of the immune system is responsible for the formation of both T-Cell and B-Cell.
B-Cells in the body are the precursor for the formation of Plasma cells. Plasma cells are responsible for the formation of antibody (immunoglobulin molecules). Multiple myeloma occurs due to the uncontrolled growth and rapid propagation of the plasma cells. Thereby, abnormal proteins are formed instead of functional immunoglobulin, including M-spike, Para protein, monoclonal proteins, and monoclonal antibody. Researcher explore the effect of two proteins P300 AND CBP and the potential drugs that inhibit the effect of these proteins.
The enzyme P300 AND CBP are two proteins that are responsible for the cancer cellular growth and also its progression. However till now there are no such drugs present that supress the action of these enzymes. Also the exact role of them in the progression of cancer is not fully understood yet.
The drug developed by those group of researchers acts as the transcription factor inhibitor that can turn off these genes and their action. Transcription is one of the main mechanism which characterizes the growth as well as metastasis of the cancer cells. Inhibiting the mechanism of transcription of the cancer cells, can put a halt to the cancer disease.
The experimental therapy along with those certain drugs, increase the efficacy of the treatment and thus it showed better result. Hitherto, actual transcription inhibitory pathway and the action of the drugs to halt the cancer mechanism is still unravelled.
